{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:09Z","timestamp":1793115309475,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"DOI":"10.1182\/bloodadvances.2026020650","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:57:50Z","timestamp":1787345870000},"page":"7069-7073","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Boosting donor chimerism after sickle cell transplants"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1766-2396","authenticated-orcid":false,"given":"Moyosoreoluwa M.","family":"Laditan","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0327-7629","authenticated-orcid":false,"given":"Ojas","family":"Somani","sequence":"additional","affiliation":[{"name":"2Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6902-0876","authenticated-orcid":false,"given":"Jeffery J.","family":"Bednarski","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hayashi","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5452-9530","authenticated-orcid":false,"given":"Melissa","family":"Mavers","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-669X","authenticated-orcid":false,"given":"Thomas","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2920","authenticated-orcid":false,"given":"Hemalatha G.","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology\/Oncology\/Blood and Marrow Transplant, Nationwide Children\u2019s Hospital, Columbus, OH"},{"name":"4Department of Pediatrics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginny","family":"Schulz","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-607X","authenticated-orcid":false,"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"5","key":"2026102711121994300_bib1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/bloodadvances.2024013926","article-title":"Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease","volume":"9","author":"Walters","year":"2025","journal-title":"Blood Adv"},{"issue":"16","key":"2026102711121994300_bib2","first-page":"3894","article-title":"Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease","volume":"4","author":"Ngwube","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026102711121994300_bib3","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/bloodadvances.2025017413","article-title":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI","volume":"10","author":"Goldenberg","year":"2026","journal-title":"Blood Adv"},{"issue":"3","key":"2026102711121994300_bib4","doi-asserted-by":"crossref","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical bone marrow transplantation for sickle cell disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid"},{"issue":"25","key":"2026102711121994300_bib5","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"Kassim","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026102711121994300_bib6","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.jtct.2022.10.012","article-title":"Long-term organ function after HCT for SCD: a report from the sickle cell transplant advocacy and research alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2026102711121994300_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2026102711121994300_bib8","doi-asserted-by":"crossref","first-page":"826.e1","DOI":"10.1016\/j.jtct.2025.06.015","article-title":"Impact of abatacept inclusive graft-versus-host disease prophylaxis in pediatric stem cell transplantation for hemoglobinopathy","volume":"31","author":"Shah","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2026102711121994300_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"Jama"},{"issue":"6","key":"2026102711121994300_bib10","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jtct.2026.02.012","article-title":"Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease","volume":"32","author":"Guilcher","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2026102711121994300_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2026102711121994300_bib12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2019.02.011","article-title":"Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease","volume":"25","author":"Guilcher","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2026102711121994300_bib13","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2026102711121994300_bib14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026102711121994300_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbmt.2014.10.010","article-title":"Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases","volume":"21","author":"Haines","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2026102711121994300_bib16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.leu.2401581","article-title":"Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children","volume":"13","author":"Bader","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"2026102711121994300_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.bmt.1704745","article-title":"Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin","volume":"35","author":"Horan","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2026102711121994300_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08880018.2021.2013369","article-title":"Post-transplant CD34+ selected stem cell boost as an intervention for declining mixed chimerism following reduced intensity conditioning allogeneic stem cell transplant in children and young adults with sickle cell disease: a case series","volume":"39","author":"Ngwube","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"2026102711121994300_bib19","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41409-022-01749-9","article-title":"CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease","volume":"57","author":"Rangarajan","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2026102711121994300_bib20","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1016\/j.jtct.2025.12.866","article-title":"Post-transplant cyclophosphamide with extended abatacept for GVHD prophylaxis following haploidentical transplantation for non-malignant disorders","volume":"32","author":"Pfeiffer","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2026102711121994300_bib21","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026102711121994300_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbmt.2017.10.012","article-title":"Second hematopoietic stem cell transplant for thalassemia major: improved clinical outcomes with a treosulfan-based conditioning regimen","volume":"24","author":"Korula","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2026102711121994300_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2009.006817","article-title":"Second bone marrow transplantation for patients with thalassemia: risks and benefits","volume":"94","author":"Stepensky","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2026102711121994300_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"2026102711121994300_bib25","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.bbmt.2018.03.013","article-title":"Post-transplant CD34(+) selected stem cell \"boost\" for mixed chimerism after reduced-intensity conditioning hematopoietic stem cell transplantation in children and young adults with primary immune deficiencies","volume":"24","author":"Chandra","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7069\/2595551\/blooda_adv-2026-020650-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7069\/2595551\/blooda_adv-2026-020650-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:28Z","timestamp":1793113948000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/7069\/570456\/Boosting-donor-chimerism-after-sickle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020650","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,16]]}}}